Table 1.
Post-transplant testing at 6 weeks and 4 months. ABMR/AMR: antibody-mediated rejection; CAV: cardiac allograft vasculopathy; CMV: cytomegalovirus; DD cfDNA = donor-derived cell-free deoxyribonucleic acid; DSAs: donor-specific antibodies; EF: ejection fraction; EMB path: endomyocardial biopsy pathology; GEP: gene expression profiling; IVUS: intravascular ultrasound; LHC: left heart catheterization; MMDx: Molecular Microscope Diagnostic System; TCMR: T-cell-mediated rejection; 1R, pAMRO: grade 1R (mild) pathology antibody-mediated rejection
| TIME POST TRANSPLANT | INDICATION | ECHO | RHC | LHC/IVUS | CMV LEVELS | GEP | DD cfDNA | DSAs | EMB Path | MMDx |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 weeks | Routine surveillance | Normal EF | Preserved hemodynamics | CAV grade 0 / IVUS grade 4 | Not detected | Not performed | 0.12% | Non | 0R, pAMR0 | No TCMR / No ABMR |
| 4 months | Bradycardia | Normal EF | Preserved hemodynamics | Not performed | Not detected | 38 | 0.48% | Positive | 1R, pAMR0 | Moderate TCMR/No ABMR |
Figure 1.
Molecular Microscope Diagnostic System report. The yellow arrow shows the biopsy. AMBR: antibody-mediated rejection; NR: normal; TCMR: T-cell-mediated rejection; PC: principal component
Figure 2.
Endomyocardial biopsy.